Academic Journal
HU308, A Selective Cannabinoid Type-2 Receptor Agonist, Mitigates SARS-COV-2 Spike Protein-Induced Acute Lung Injury in Mice
| Τίτλος: | HU308, A Selective Cannabinoid Type-2 Receptor Agonist, Mitigates SARS-COV-2 Spike Protein-Induced Acute Lung Injury in Mice |
|---|---|
| Συγγραφείς: | Lockett, Janette, Nicholson, Gregory, Richards, Nicholas, Washington, Ryan, Nagre, Nagaraja |
| Πηγή: | Department of Biomedical and Translational Sciences Faculty Publications |
| Στοιχεία εκδότη: | ODU Digital Commons |
| Έτος έκδοσης: | 2026 |
| Συλλογή: | Old Dominion University: ODU Digital Commons |
| Θεματικοί όροι: | Acute lung injury, Acute lung injury/drug therapy/metabolism/chemically induces, Animals, Bronchoalveolar lavage fluid, Cannabinoid-2 receptor, Cannabinoids, Cannabinoids/pharmacology, Cannabinoid receptor agonists/pharmacology, Covid-19, COVID-19 Drug treatment, Cytokines/metabolism, Disease models, animal, Lung/drug effects/pathology, metabolism, Male, Mice, inbred C57BL, NF-kappa B/Metabolism, Receptor, Cannabinoid, CB2/agonists, SARS-CoV-2, SARS-CoV-2 spike protein subunit 1, Spike glycoprotein, Coronavirus, Chemicals and Drugs, Influenza Humans, Influenza Virus Vaccines |
| Περιγραφή: | Introduction The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to pose major health challenges despite effective vaccination efforts. The sustained occurrence of breakthrough infections and emerging variants of the virus highlights the need for additional therapeutic strategies. Given the anti-inflammatory role of the cannabinoid type 2 receptor (CB2R), we examined the effect of CB2R activation in SARS-CoV-2 spike protein subunit 1 (S1SP)-induced acute lung injury (ALI). Methods ALI was induced in mice by intratracheal (i.t.) administration of S1SP, followed by treatment with the CB2R agonist HU308 (5 mg/kg, intraperitoneal: i.p.) 1 h post-S1SP and every 24 h thereafter. Lung function, bronchoalveolar lavage fluid (BALF) parameters, cytokine levels, and inflammatory signaling were assessed at 48 h following S1SP exposure. Results HU308 treatment significantly reduced S1SP-induced pulmonary dysfunction, immune cell infiltration, neutrophil activation, and proinflammatory cytokine production, while suppressing NF-κB and STAT3 activation. HU308 treatment restored the Nrf2 expression in the lung. Conclusion CB2R activation ameliorates S1SP-induced lung inflammation and injury, suggesting its therapeutic potential against COVID-19-related ALI. |
| Τύπος εγγράφου: | text |
| Περιγραφή αρχείου: | application/pdf |
| Γλώσσα: | unknown |
| Relation: | https://digitalcommons.odu.edu/biomedical_pubs/28; https://digitalcommons.odu.edu/context/biomedical_pubs/article/1027/viewcontent/Lockett_2026_HU308ASelectiveCannabinoidType2OCRed.pdf; https://digitalcommons.odu.edu/context/biomedical_pubs/article/1027/filename/1/type/additional/viewcontent/408_2026_870_MOESM1_ESM.docx |
| DOI: | 10.1007/s00408-026-00870-6 |
| Διαθεσιμότητα: | https://digitalcommons.odu.edu/biomedical_pubs/28 https://doi.org/10.1007/s00408-026-00870-6 https://digitalcommons.odu.edu/context/biomedical_pubs/article/1027/viewcontent/Lockett_2026_HU308ASelectiveCannabinoidType2OCRed.pdf https://digitalcommons.odu.edu/context/biomedical_pubs/article/1027/filename/1/type/additional/viewcontent/408_2026_870_MOESM1_ESM.docx |
| Rights: | © 2026 The Authors. This article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License , which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. |
| Αριθμός Καταχώρησης: | edsbas.F71346B8 |
| Βάση Δεδομένων: | BASE |
| DOI: | 10.1007/s00408-026-00870-6 |
|---|